ERBB2 and breast cancer: However, in HER2-overexpressing breast cancer cells, the use of Grp94-specific inhibitors strongly affected cell viability [15], suggesting that Grp94 involvement in cytoprotection reflects cell- or tissue-specific mechanisms.